Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Panthenol→

Panthenol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
16485-10-2
Molecular formula
C9H19NO4
Molecular weight
205.25 g/mol
Drug class
Provitamin B5 (pantothenol)Pantothenic acid precursor
Mechanism of action
Dexpanthenol, the biologically active D-isomer, is enzymatically converted to pantothenic acid (vitamin B5), a precursor of coenzyme A. DL-panthenol is a racemic mixture; the L-isomer does not provide the same vitamin activity.
Indications / reported uses
  • Reported topical cosmetic use for skin moisturisation and support of epithelial repair; the racemic DL-panthenol entry is not itself associated with an FDA-approved drug indication in the cited PubChem record

Sources: PubChem — DL-panthenol identity, pharmacology and indication status · PubChem — Dexpanthenol conversion to pantothenic acid · German Chemical Society — Panthenol cosmetic use and D/L isomer distinction

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Panthenol Environmental Risk Assessment (ERA) (the Panthenol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.